Yorktown Management & Research Co Inc Has $1.38 Million Position in Insmed, Inc. $INSM

Yorktown Management & Research Co Inc lifted its holdings in Insmed, Inc. (NASDAQ:INSM) by 64.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 9,600 shares of the biopharmaceutical company’s stock after purchasing an additional 3,750 shares during the period. Insmed accounts for approximately 1.1% of Yorktown Management & Research Co Inc’s portfolio, making the stock its 14th biggest holding. Yorktown Management & Research Co Inc’s holdings in Insmed were worth $1,382,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Stone House Investment Management LLC acquired a new position in Insmed during the 3rd quarter worth $29,000. MassMutual Private Wealth & Trust FSB increased its holdings in shares of Insmed by 59.6% in the third quarter. MassMutual Private Wealth & Trust FSB now owns 217 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 81 shares in the last quarter. Hilltop National Bank acquired a new stake in shares of Insmed during the second quarter worth $28,000. ORG Partners LLC boosted its position in shares of Insmed by 220.2% during the second quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 196 shares during the period. Finally, FNY Investment Advisers LLC acquired a new position in shares of Insmed during the 2nd quarter worth approximately $33,000.

Insider Transactions at Insmed

In other news, CEO William Lewis sold 19,215 shares of the business’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $169.00, for a total value of $3,247,335.00. Following the completion of the transaction, the chief executive officer owned 306,891 shares in the company, valued at $51,864,579. The trade was a 5.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Sara Bonstein sold 1,447 shares of the firm’s stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $174.17, for a total value of $252,023.99. Following the completion of the transaction, the chief financial officer directly owned 80,506 shares in the company, valued at approximately $14,021,730.02. This represents a 1.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 286,100 shares of company stock valued at $52,595,894 in the last three months. Company insiders own 3.00% of the company’s stock.

Analyst Upgrades and Downgrades

INSM has been the subject of several recent research reports. Wells Fargo & Company set a $195.00 price target on Insmed in a research note on Thursday, December 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Insmed in a research note on Wednesday, October 8th. TD Cowen dropped their price target on shares of Insmed from $269.00 to $241.00 and set a “buy” rating for the company in a research report on Thursday, December 18th. The Goldman Sachs Group lifted their price objective on shares of Insmed from $225.00 to $258.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Finally, HC Wainwright cut their target price on shares of Insmed from $240.00 to $230.00 and set a “buy” rating on the stock in a research report on Thursday, December 18th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $205.77.

Insmed Stock Up 1.3%

Shares of NASDAQ INSM opened at $161.42 on Friday. The business has a 50-day simple moving average of $187.73 and a two-hundred day simple moving average of $154.36. The company has a market cap of $34.43 billion, a P/E ratio of -26.08 and a beta of 1.08. The company has a quick ratio of 4.34, a current ratio of 4.63 and a debt-to-equity ratio of 0.59. Insmed, Inc. has a 52 week low of $60.40 and a 52 week high of $212.75.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). The company had revenue of $142.34 million during the quarter, compared to analysts’ expectations of $114.33 million. Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. The company’s revenue for the quarter was up 52.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.27) earnings per share. Research analysts anticipate that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.